CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Amicus Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Amicus Therapeutics, Inc.
3675 Market Street
Phone: (215) 921-7600p:215 921-7600 PHILADELPHIA, PA  19104  United States Ticker: FOLDFOLD
Business Summary
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Michael G.Raab 58 3/4/2024 1/1/2004
President, Chief Executive Officer, Director Bradley L.Campbell 47 8/1/2022 5/1/2007
Chief Financial Officer Simon N.Harford 60 8/21/2023 8/21/2023
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
AMICUS THERAPEUTICS UK LIMITED PHOENIX HOUSE, OXFORD ROAD,,TATLING END, GERRAD'S CROSS UNITED KINGDOM
Scioderm, Inc. 9560 Strickland Road Raleigh NC United States

Business Names
Business Name
Amicus Biologics, Inc.
Amicus GT Holdings, LLC (Delaware)
Amicus Therapeutics ApS
24 additional Business Names available in full report.

General Information
Number of Employees: 517 (As of 12/31/2023)
Outstanding Shares: 295,382,614 (As of 2/13/2024)
Shareholders: 17
Stock Exchange: NASD
Federal Tax Id: 200422823
Fax Number: (609) 662-2001
Email Address: info@amicustherapeutics.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024